Stay updated on Setmelanotide in BBS and AS for Obesity Clinical Trial
Sign up to get notified when there's something new on the Setmelanotide in BBS and AS for Obesity Clinical Trial page.
![Latest website image capture](/pages/_next/image?url=https%3A%2F%2Fs3.us-west-2.amazonaws.com%2Fvp-files-ore%2Fresources%2F12months%2F8ync-51bAEVHJDoU2iZjGQcdefU.uncropped.jpg&w=3840&q=75)
Latest updates to the Setmelanotide in BBS and AS for Obesity Clinical Trial page
- ChecktodayNo Change Detected
- CheckyesterdayNo Change Detected
- Check3 days agoNo Change Detected
- Check4 days agoChange DetectedThe study has expanded to include 12 locations, and the revision has been updated from v2.9.7 to v2.10.0.SummaryDifference0.3%
- Check5 days agoNo Change Detected
- Check11 days agoChange DetectedThe website has been updated to Revision v2.9.7 from v2.9.6.SummaryDifference0.1%
- Check25 days agoChange DetectedThe value of Revision has been updated from v2.9.5 to v2.9.6, indicating a recent revision in the content of the webpage.SummaryDifference0.1%
- Check30 days agoChange DetectedThe value of Revision has been updated from v2.9.3 to v2.9.5, indicating a recent revision in the content of the webpage.SummaryDifference0.1%
- Check31 days agoChange DetectedThe value of Revision has been updated from v2.9.1 to v2.9.3, indicating a recent revision in the content of the webpage.SummaryDifference0.1%
- Check32 days agoChange DetectedThe value on the web page has changed from 'Show more Revision: v2.9.0' to 'MedlinePlus Genetics related topics: Bardet-Biedl syndrome, Alström syndrome, and more. Design details, primary and secondary outcome measures, and study plan for a Phase 3 trial of Setmelanotide in Bardet-Biedl Syndrome and Alström Syndrome participants with moderate to severe obesity.'SummaryDifference45%
Stay in the know with updates to Setmelanotide in BBS and AS for Obesity Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Setmelanotide in BBS and AS for Obesity Clinical Trial page.